A new market study on the 2022-2028 Regenerative Therapies Market with 100+ market data Tables, Pie Chat, and Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry-validated market data. The report incorporates a broad evaluation of different methods like combinations and acquisitions, thing headways, and investigation and enhancements embraced by observable market pioneers to stay at the front line in the overall market.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/3712
Regenerative therapies use a patient’s own cells to repair damaged tissues. Typically, these stem cells come from the patient’s own bone marrow or fat tissue. The term “regenerative” is an umbrella term for various procedures that use substances from the body to treat various ailments. A doctor can administer one or more of these therapies depending on the nature of the disease. The recovery period can last several weeks or even months, so the benefits can be immediate.
The global regenerative therapies market is estimated to account for US$ 10,421.5 Mn in terms of value in 2019 and is expected to reach US$ 45,940.7 Mn by the end of 2027.
Global Regenerative Therapies Market: Drivers
Growing popularity of stem cell technique is expected to propel growth of the global regenerative therapies market over the forecast period. For instance, according to the study, “The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions”, published in the journal Perspectives in Biology and Medicine, in 2018, the number of new stem cell businesses with websites doubled on average every year between 2009 and 2014, in the U.S.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/3712
Global Regenerative Therapies Market: Opportunities
High prevalence of neurological disorders is expected to provide lucrative growth opportunities for players in the market. For instance, according to the study, “Prevalence of Parkinson’s disease (PD) across North America”, published in July 2018 in the journal Nature, the number of people suffering from PD is expected to reach 930,000 in 2020 and 1,238,000 in 2030.
Global Regenerative Therapies Market: Restraints
Factor such as lack of financial-backing of smaller firms is projected to restrict growth of the global regenerative therapies market. A common factor in the regenerative therapies industry is the unavailability of proper financing options for smaller organizations. This is one of the key factors hampering R&D in the field of regenerative therapies. Quite observed in resource-poor settings, many promising targets have been abandoned half way during clinical trial phase due to lack of financing support stemming from insufficient data on proven efficacy. Moreover, emergence of start-ups researching on and producing regenerative therapies has been hampered by lack of lucrative co-marketing collaborations from medical devices companies (especially in orthopedics – the largest application segment in terms of revenue generation) and in-licensing and out-licensing deals.
Key Takeaways:
Allograft held dominant position in the global regenerative therapies market in 2019, accounting for 57.7% share in terms of value, followed by xenograft and alloplast, respectively. Allograft is a biological regenerative material which is transplanted from one person to other i.e. from a donor to receiver. Growing applications of this product is expected to support growth of the segment.
Orthopedic segment held dominant position in the global regenerative therapies market in 2019, accounting for 37.2% share in terms of value, followed by soft tissue repair, and cardiovascular, respectively. Increasing research activities and rapid development of innovative products by key players is expected to uplift growth of the segment. For instance, in 2015, NuVasive Inc.—U.S.-based company—launched its new innovative biologics technology, AttraX Putty, which is a synthetic bone graft, indicated in posterolateral spinal surgery as an autograft extender.
Hospitals segment held dominant position in the global regenerative therapies market in 2019, accounting for 84.3% share in terms of value, followed by ambulatory surgical centers and educational institutes, respectively.
Market Trends
Key players are focused on developing novel platforms biological therapeutic products to expand their product portfolio. For instance, in March 2020, Pluristem Therapeutics Inc., a regenerative medicine company, announced that it has dosed three patients in two different hospitals in Israel under a compassionate use program for the treatment of COVID-19.
Key players are also focused on expanding their capabilities. For instance, in March 2020, BioStem Life Sciences, a subsidiary of BioStem Technologies Inc. and a developer of regenerative therapies, announced to add R&D laboratory to its Florida, U.S. facility.
Regulations
Europe
The translational pipeline from basic research to the delivery of innovative stem cell-based therapies is covered by a variety of European legal instruments, ranging from regulations on marketing authorization (Regulation (EC) no. 1394/2007) to Directives about clinical trials (Directive 2001/20/EC) and guidelines of good clinical practice (Directive 2001/83/EC, Directive 2009/120/EC).
Global Regenerative Therapies Market: Competitive Landscape
Major players operating in the global regenerative therapies market include, Shire Pharmaceuticals, Kinetic Concepts, Inc., Mesoblast Ltd., Nuo Therapeutics (Cytomedix Inc.), Advanced Cell Technology, Inc., BioStem Life Sciences, Akron Biotechnology, LLC, Organovo Holdings Inc., Orgenesis Inc., Pluristem Therapeutics Inc., Genzyme, Athersys, Inc., RenovaCare, Inc., and Cytori Therapeutics, Inc.
March 2020: BioStem Life Sciences received its ISBT 128 Registration from the International Council for Commonality in Blood Banking Automation
February 2019: Pluristem Therapeutics Inc. collaborated with NASA’s Ames Research Center to evaluate the potential of its PLX cell therapies in preventing and treating medical conditions caused during space missions
Segmentation
- By Tissue Type
- Allograft
- Xenograft
- Alloplast
- By Application
- Soft Tissue Repair
- Cardiovascular
- Dental
- Orthopedic
- CNS disease treatment
- Others
- By End User
- Hospitals
- Ambulatory Surgical Centers
- Educational Institutes
- By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Buy This Report And Get Quick Access( Flat USD 2000 OFF ) – https://www.coherentmarketinsights.com/promo/buynow/3712
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837